The University of Hong Kong developed a dual checkpoint inhibitor therapy combining nivolumab and ipilimumab for unresectable hepatocellular carcinoma, receiving authorization across multiple international regulatory bodies. This immunotherapy combination targets complementary immune pathways to enhance anti-tumor efficacy and improve survival outcomes in advanced liver cancer, representing a significant therapeutic advancement for a malignancy traditionally resistant to available treatments.